Long‐Term Downregulation of the Sodium Channel Gene Scn8a Is Therapeutic in Mouse Models of SCN8A Epilepsy
Annals of Neurology · 2024-04 · 95 (4) · 754-759
DOI: 10.1002/ana.26861 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 06.01.2024. Verfasst von Sophie F Hill und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Graduate Program, University of Michigan, Ann Arbor, MI, United States. Hauptthemen laut MEDLINE: Epilepsy. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, Horace H. Rackham School of Graduate Studies, University of Michigan, Dravet Syndrome Foundation.
Abstract (Originalsprache)
Objective
De novo mutations of the voltage‐gated sodium channel gene SCN8A cause developmental and epileptic encephalopathy (DEE). Most pathogenic variants result in gain‐of‐function changes in activity of the sodium channel Na v 1.6, poorly controlled seizures, and significant comorbidities. In previous work, an antisense oligonucleotide (ASO) reduced Scn8a transcripts and increased lifespan after neonatal administration to a mouse model. Here, we tested long‐term ASO treatment initiated after seizure onset, as required for clinical application.
Methods
ASO treatment was initiated after observation of a convulsive seizure and repeated at 4 to 6 week intervals for 1 year. We also tested the long‐term efficacy of an AAV10‐short hairpin RNA (shRNA) virus administered on P1.
Results
Repeated treatment with the Scn8a ASO initiated after seizure onset provided long‐term survival and reduced seizure frequency during a 12 month observation period. A single treatment with viral shRNA was also protective during 12 months of observation.
Interpretation
Downregulation of Scn8a expression that is initiated after the onset of seizures is effective for long‐term treatment in a model of SCN8A ‐DEE. Repeated ASO administration or a single dose of viral shRNA prevented seizures and extended survival through 12 months of observation. ANN NEUROL 2024;95:754–759
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Neuroscience Graduate Program, University of Michigan, Ann Arbor, MI, United States.
- Department of Human Genetics, University of Michigan, Ann Arbor, MI.
- Department of Pediatrics, University of Michigan, Ann Arbor, MI.
- Department of Neurology, University of Michigan, Ann Arbor, MI.
ORCID-Profile: Wenxi Yu
Förderung
- NINDS NIH HHS
- Horace H. Rackham School of Graduate Studies, University of Michigan
- Dravet Syndrome Foundation
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Hill, S. F., Yu, W., Ziobro, J., Chalasani, S., Reger, F., & Meisler, M. H. (2024). Long‐Term Downregulation of the Sodium Channel Gene Scn8a Is Therapeutic in Mouse Models of SCN8A Epilepsy. Annals of Neurology, 95(4), 754-759. https://doi.org/10.1002/ana.26861
Vancouver
Hill SF, Yu W, Ziobro J, Chalasani S, Reger F, Meisler MH. Long‐Term Downregulation of the Sodium Channel Gene Scn8a Is Therapeutic in Mouse Models of SCN8A Epilepsy. Annals of Neurology. 2024;95(4):754-759. doi:10.1002/ana.26861
BibTeX
@article{Hill2024,
author = {Hill, Sophie F and Yu, Wenxi and Ziobro, Julie and Chalasani, Sanjna and Reger, Faith and Meisler, Miriam H},
title = {Long‐Term Downregulation of the Sodium Channel Gene Scn8a Is Therapeutic in Mouse Models of SCN8A Epilepsy},
journal = {Annals of Neurology},
year = {2024},
volume = {95},
number = {4},
pages = {754--759},
doi = {10.1002/ana.26861}
}
EUVIMED